Real World Evidence

The health and fitness wearable market is on the rise since the last few years. Analysts expect that by 2020, almost half a billion smart wearable devices will have been sold. However, despite the fast-growing market, only 10% of those consumers are using the product daily. This is an opportunity for innovative life science companies to […]

Real-world evidence (RWE) research is gaining significant importance in biopharmaceutical product development as well as its commercialization. The increasing need of the industry to seek broader information about the safety and effectiveness in the real-world setting, which typically impacts the ensuing reimbursement and utilization of new products, is determined by regulators, public and private payers, […]

Traditionally, the pharmaceutical industry has always been dependent upon the ‘push’ strategy for successful market access for products. The drug approval process, involving submission of data on efficacy, safety, and tolerability to the regulatory agencies, used to be simple; which ended with the drug being marketed to the targeted physicians and dispensed by pharmacies post approval. Thus, this whole process involved a limited set of stakeholders, viz. physicians, regulatory agencies, and pharmacies.

Traditionally, the pharmaceutical industry has always been dependent upon the ‘push’ strategy for successful market access for products. The drug approval process, involving submission of data on efficacy, safety, and tolerability to the regulatory agencies, used to be simple; which ended with the drug being marketed to the targeted physicians and dispensed by pharmacies post approval. Thus, […]

The term real-world evidence (RWE) commonly applies to data generated in non-randomized clinical trials (RCTs) in a healthcare setting, which sometimes also covers patient socio-economic data and environmental data. Irrespective of the definition, RWE offers significant advantages over RCTs that have well documented limitations, despite being recognized as the gold standard for evidence-based medicine. Today, […]

Missing data are a big concern in any research project and are often unavoidable in spite of investigators’ best efforts. Missing outcomes have two effects: reduced precision and power, and bias. Also, the loss of precision is inevitable, except the possible use of the available data; e.g. to be sure not to exclude from the […]

                Workshop title – “R WE Ready?” – “Real World Evidence” Methods! Organisers – Co-organised by Organisation of Pharmaceutical Producers of India (OPPI) and ISPOR India-Mumbai Chapter Objectives – To enhance skill set of the professionals of the medical affairs community in area of real world evidence generation to […]

We all want safe and effective medicines to reach patients as soon as possible, but as we know, drug development, market authorization and payer assessment are all slow sections of a long and drawn out journey for a drug. But what if patients could have access to medicines not just months earlier, but potentially 8 […]